Author Interviews, JAMA, Prostate Cancer, Race/Ethnic Diversity, UCLA / 03.01.2022

MedicalResearch.com Interview with: Ting Martin Ma, MD, PhD Resident Physician Amar U. Kishan, MD Assistant Professor, Department of Radiation Oncology Vice-Chair of Clinical and Translational Research Department of Radiation Oncology at UCLA MedicalResearch.com: What is the background for this study? Response: We know from epidemiologic studies that  Black men are more likely to be diagnosed with and die of prostate cancer than White men. Recent studies hinted that Black men had better oncological outcome (such as prostate cancer specific mortality and overall survival) responding to systemic therapy for advanced prostate cancer (e.g. cancer that has spread or metastasized to other parts of the body). The question we were trying to answer in this study is: is there a difference in outcomes between Black and White men with localized prostate cancer (cancer that has not spread) receiving definitive radiotherapy enrolled in clinical trials?  (more…)
Author Interviews, Exercise - Fitness, JAMA, Prostate Cancer / 24.08.2021

MedicalResearch.com Interview with: Kerry S. Courneya, PhD Professor and Canada Research Chair in Physical Activity and Cancer Director, Behavioral Medicine Laboratory and Fitness Center Faculty of Kinesiology, Sport, and Recreation | College of Health Sciences University of Alberta | Edmonton, Alberta | CANADA  MedicalResearch.com: What is the background for this study? Response: An increasing number of men with low risk prostate cancer (PCa) do not receive any immediate medical treatments for their PCa. This practice is called active surveillance (AS). It can be very stressful for men because about one-third of them will eventually experience disease progression and require medical treatments. Right now, there is nothing these men can really do for themselves other than to attend all of their follow-up medical visits. Some research has shown that exercise may slow the progression of prostate tumours and metastasis in animal models and improve quality of life in men during and after PCa treatments. Very little research, however, has been conducted in the AS setting. We wanted to see if a high intensity interval training exercise program could improve fitness and prevent or delay biochemical progression of PCa in the AS setting. (more…)
Author Interviews, Cancer Research, COVID -19 Coronavirus, JAMA, Prostate Cancer, Race/Ethnic Diversity / 23.07.2021

MedicalResearch.com Interview with: Andres F. Correa, MD Assistant Professor Department of Surgical Oncology, and Adrien Bernstein, MD Second Year Urologic Oncology Fellow Fox Chase Cancer Center MedicalResearch.com: What is the background for this study? Response: Unfortunately, it has been well-established that historically Black Americans experience increased cancer specific mortality compared to white patients. In prostate cancer specifically studies have shown that when access to care is equitable this gap resolves. This suggests that biological factors are not driving these differences but rather the result of the complex interplay of social determinants and systemic inequities in our healthcare system. Early in the pandemic, multiple studies demonstrated that minority communities disproportionately shouldered poor COVID-19 outcomes.  On March 13th 2020, the American College of Surgeons recommended against elective procedures; however, the definition of an elective oncologic case was left to the discretion of the provider. As prostate cancer treatment can be safely deferred up to a year follow diagnosis, management of prostate cancer during the initial lockdown period of the COVID-19 Pandemic provided a useful analysis of the differential restrictions placed on non-emergent health care during the Pandemic. (more…)
Author Interviews, Brigham & Women's - Harvard, Journal Clinical Oncology, Prostate Cancer, Radiation Therapy / 04.06.2021

MedicalResearch.com Interview with: Anthony D'Amico, MD, PhD Professor and Chief of Genitourinary Radiation Oncology Brigham and Women's Hospital and Dana-Farber Cancer Institute MedicalResearch.com: What is the background for this study? Response: 3 randomized trials published in Sept, 2020 in the Lancet and Lancet Oncology concluded that delivering radiation therapy (RT) after surgery for prostate cancer   when the PSA rises signaling recurrence (i.e. early salvage RT) as opposed to when the PSA is undetectable (i.e. adjuvant RT) did not compromise subsequent cancer progression. However these trials may have missed the benefit of adjuvant RT because a minority of men (9 to 17% of the study cohorts) were found to have adverse factors at prostatectomy which are associated with cancer progression and death from prostate cancer. Specifically, men with adverse pathology at prostatectomy comprise the vast majority of men who go on to die from prostate cancer and therefore have the most to gain from adjuvant RT. Yet, given the results of the 3 randomized trials many physicians are no longer offering adjuvant RT, even in men with adverse pathology at surgery. (more…)
Author Interviews, Lipids, Prostate Cancer / 03.06.2021

MedicalResearch.com Interview with: Michelle Hill, PhD Head, Precision & Systems Biomedicine Group QIMR Berghofer Medical Research Institute MedicalResearch.com: What is the background for this study? Response: The role of cholesterol and cholesterol lowering drug therapy in prostate cancer has been previously investigated with mixed results. Our previous laboratory studies indicate that high cholesterol diet accelerates the spreading of advanced prostate cancer. We also observed a change of the cellular location of cholesterol, from the cell periphery (plasma membrane) to inside the cell. This study investigates the how the change in cholesterol location promotes prostate cancer spread. (more…)